Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth

Vaccine

Volumn 35, Issue 43, 2017, Pages 5842-5849

  Bryson, Paul D ^a   Han, Xiaolu ^b   Truong, Norman ^a   Wang, Pin ^a,c  

^a University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alpha lactalbumin; Breast cancer immunotherapy; Cancer vaccine; ERBB2 Her2; Lentiviral vector

Indexed keywords

ALPHA LACTALBUMIN; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LENTIVIRUS VECTOR; SINDBIS VIRUS GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; AUTOANTIGEN; MAMMARY CARCINOMA ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ERBB2 GENE; FEMALE; IMMUNIZATION; IN VIVO STUDY; LALBA GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH INHIBITION RATE; TUMOR IMMUNITY; WILD TYPE MOUSE; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; EXPERIMENTAL MAMMARY NEOPLASM; GENE VECTOR; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRUS; PROCEDURES;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; IMMUNOTHERAPY; LENTIVIRUS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2;

EID: 85029147266     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.017     Document Type: Article

References (45)

1. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA: a cancer J Clinic 64:1 (2014), 9–29, 10.3322/caac.21208.
2. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England J Med 344:11 (2001), 783–792.
3. Dawood, S., Broglio, K., Buzdar, A.U., Hortobagyi, G.N., Giordano, S.H., Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:1 (2010), 92–98, 10.1200/JCO.2008.19.9844.
4. Palena, C., Schlom, J., Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol, 2010, 2010, 380697, 10.1155/2010/380697.
5. Klebanoff, C.A., Acquavella, N., Yu, Z., Restifo, N.P., Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1 (2011), 27–44, 10.1111/j.1600-065X.2010.00979.x.
6. Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat Rev 12:4 (2012), 265–277, 10.1038/nrc3258.
7. Bryson, P.D., Wang, P., Lentivector Vaccines. Lattime, E.C., Gerson, S.L., (eds.) Gene therapy of cancer: translational approaches from preclinical studies to clinical implementation, 3rd edn., 2014, Academic Press, Amsterdam.
8. Breckpot, K., Aerts, J.L., Thielemans, K., Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 14:11 (2007), 847–862, 10.1038/sj.gt.3302947.
9. Ageichik, A., Buchholz, C.J., Collins, M.K., Lentiviral vectors targeted to MHC II are effective in immunization. Human Gene Therapy 22:10 (2010), 1249–1254.
10. Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K.I., Ziegler, L., Elliot, A., Walls, A., Yu, D., Baltimore, D., Wang, P., Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotech 26:3 (2008), 326–334, 10.1038/nbt1390.
11. Yang, H.G., Hu, B.L., Xiao, L., Wang, P., Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther 18:5 (2011), 370–380, 10.1038/cgt.2011.13.
12. Cheever, M.A., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht, T.T., Mellman, I., Prindiville, S.A., Viner, J.L., Weiner, L.M., Matrisian, L.M., The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res: Off J Am Associat Cancer Res 15:17 (2009), 5323–5337, 10.1158/1078-0432.CCR-09-0737.
13. Narayanan, K., Jaramillo, A., Benshoff, N.D., Campbell, L.G., Fleming, T.P., Dietz, J.R., Mohanakumar, T., Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst 96:18 (2004), 1388–1396, 10.1093/jnci/djh261.
14. Jaini, R., Kesaraju, P., Johnson, J.M., Altuntas, C.Z., Jane-Wit, D., Tuohy, V.K., An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 16:7 (2010), 799–803.
15. Gilewski, T., Adluri, S., Ragupathi, G., Zhang, S., Yao, T.J., Panageas, K., Moynahan, M., Houghton, A., Norton, L., Livingston, P.O., Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:5 (2000), 1693–1701.
16. Seil, I., Frei, C., Sultmann, H., Knauer, S.K., Engels, K., Jager, E., Zatloukal, K., Pfreundschuh, M., Knuth, A., Tseng-Chen, Y., Jungbluth, A.A., Stauber, R.H., Jager, D., The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 120:12 (2007), 2635–2642, 10.1002/ijc.22620.
17. Ladjemi, M.Z., Jacot, W., Chardes, T., Pelegrin, A., Navarro-Teulon, I., Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59:9 (2010), 1295–1312, 10.1007/s00262-010-0869-2.
18. Arlen, P.M., Pazdur, M., Skarupa, L., Rauckhorst, M., Gulley, J.L., A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clinical breast cancer 7:2 (2006), 176–179, 10.3816/CBC.2006.n.032.
19. Tiriveedhi, V., Tucker, N., Herndon, J., Li, L., Sturmoski, M., Ellis, M., Ma, C., Naughton, M., Lockhart, A.C., Gao, F., Fleming, T., Goedegebuure, P., Mohanakumar, T., Gillanders, W.E., Safety and preliminary evidence of biologic efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 20:23 (2014), 5964–5975, 10.1158/1078-0432.ccr-14-0059.
20. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE, Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Annal Oncol 25:9 (2014), 1735–1742, 10.1093/annonc/mdu211.
21. Tuohy, V.K., Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. Expert Rev Vaccines 13:12 (2014), 1447–1462, 10.1586/14760584.2014.953063.
22. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science (New York, NY 295 (5556):868–872.
23. Finkle, D., Quan, Z.R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W.L., Hollingshead, P., Schwall, R., Koeppen, H., Erickson, S., HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10:7 (2004), 2499–2511.
24. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.) (2011) Guide for the care and use of laboratory animals.
25. Liu, Y., Tai, A., Joo, K.I., Wang, P., Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells. PLoS One, 8(6), 2013, e67400, 10.1371/journal.pone.0067400.
26. Bryson PD, Zhang C, Lee CL, Wang P (2013) A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells. J Vis Exp (76). doi:10.3791/50606.
27. Dai, B., Xiao, L., Bryson, P.D., Fang, J., Wang, P., PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol Ther 20:9 (2012), 1800–1809, 10.1038/mt.2012.98.
28. Triulzi, C., Vertuani, S., Curcio, C., Antognoli, A., Seibt, J., Akusjarvi, G., Wei, W.Z., Cavallo, F., Kiessling, R., Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer research 70:19 (2010), 7431–7441, 10.1158/0008-5472.CAN-10-0493.
29. Czerniecki, B.J., Koski, G.K., Koldovsky, U., Xu, S., Cohen, P.A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K.R., Weinstein, S., Orel, S.G., Vonderheide, R., Coukos, G., DeMichele, A., Araujo, L., Spitz, F.R., Rosen, M., Levine, B.L., June, C., Zhang, P.J., Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer research 67:4 (2007), 1842–1852, 10.1158/0008-5472.CAN-06-4038.
30. Jacob, J.B., Quaglino, E., Radkevich-Brown, O., Jones, R.F., Piechocki, M.P., Reyes, J.D., Weise, A., Amici, A., Wei, W.Z., Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 70:1 (2010), 119–128, 10.1158/0008-5472.CAN-09-2554.
31. Mossoba, M.E., Walia, J.S., Rasaiah, V.I., Buxhoeveden, N., Head, R., Ying, C., Foley, J.E., Bramson, J.L., Fowler, D.H., Medin, J.A., Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 16:3 (2008), 607–617, 10.1038/sj.mt.6300390.
32. Whittington, P.J., Radkevich-Brown, O., Jacob, J.B., Jones, R.F., Weise, A.M., Wei, W.Z., Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunol Immunother 58:5 (2009), 759–767, 10.1007/s00262-008-0599-x.
33. Pulaski, B.A., Ostrand-Rosenberg, S., Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:7 (1998), 1486–1493.
34. De Giovanni, C., Nicoletti, G., Quaglino, E., Landuzzi, L., Palladini, A., Ianzano, M.L., Dall'ora, M., Grosso, V., Ranieri, D., Laranga, R., Croci, S., Amici, A., Penichet, M.L., Iezzi, M., Cavallo, F., Nanni, P., Lollini, P.L., Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res, 16(1), 2014, R10, 10.1186/bcr3602.
35. Wei, W.Z., Shi, W.P., Galy, A., Lichlyter, D., Hernandez, S., Groner, B., Heilbrun, L., Jones, R.F., Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:5 (1999), 748–754.
36. Nakashima, H., Terabe, M., Berzofsky, J.A., Husain, S.R., Puri, R.K., A novel combination immunotherapy for cancer by IL-13Ralpha2-targeted DNA vaccine and immunotoxin in murine tumor models. J Immunol 187:10 (2011), 4935–4946, 10.4049/jimmunol.1102095.
37. Liao, D., Liu, Z., Wrasidlo, W.J., Luo, Y., Nguyen, G., Chen, T., Xiang, R., Reisfeld, R.A., Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res 71:17 (2011), 5688–5696, 10.1158/0008-5472.CAN-11-1264.
38. Cho, H.I., Celis, E., Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother 61:3 (2012), 343–351, 10.1007/s00262-011-1110-7.
39. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New York, NY 331 (6024):1565-1570.
40. McGarrity, G.J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R.N., Kinder, C., Zolopa, A., Binder-Scholl, G., Tebas, P., June, C.H., Humeau, L.M., Rebello, T., Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med 15:2 (2013), 78–82, 10.1002/jgm.2691.
41. Somaiah, N., Block, M.S., Kim, J.W., Shapiro, G., Hwu, P., Eder, J.P., Jones, R.L., Gnjatic, S., Lu, H., Phase, Hsu F.J., I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. ASCO Annual Meeting Proceedings, 2015, 3021.
42. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science (New York, NY 310 (5748):644-648. doi:10.1126/science.1117679.
43. Chin, K., DeVries, S., Fridlyand, J., Spellman, P.T., Roydasgupta, R., Kuo, W.L., Lapuk, A., Neve, R.M., Qian, Z., Ryder, T., Chen, F., Feiler, H., Tokuyasu, T., Kingsley, C., Dairkee, S., Meng, Z., Chew, K., Pinkel, D., Jain, A., Ljung, B.M., Esserman, L., Albertson, D.G., Waldman, F.M., Gray, J.W., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10:6 (2006), 529–541, 10.1016/j.ccr.2006.10.009.
44. Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.A., Hengstler, J.G., Kolbl, H., Gehrmann, M., The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:13 (2008), 5405–5413, 10.1158/0008-5472.CAN-07-5206.
45. Symmans, W.F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., Delaloge, S., Bauernhofer, T., Valero, V., Booser, D.J., Hortobagyi, G.N., Pusztai, L., Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:27 (2010), 4111–4119, 10.1200/JCO.2010.28.4273.